EnteroMedics Inc  

(Public, NASDAQ:RSLS)   Watch this stock  
Find more results for NASDAQ:ETRM
-0.02 (-0.98%)
Real-time:   2:35PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.00 - 2.12
52 week 1.60 - 30.41
Open 2.11
Vol / Avg. 248,077.00/1.57M
Mkt cap 29.57M
P/E     -
Div/yield     -
EPS -16.61
Shares 14.57M
Beta 3.06
Inst. own 3%
Oct 3, 2017
EnteroMedics Inc., ReShape Medical Inc. - M&A Call - Webcast
Sep 26, 2017
EnteroMedics Inc at Ladenburg Thalmann Healthcare Conference
Aug 8, 2017
Q2 2017 EnteroMedics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -7350.29% -2969.62%
Operating margin -7386.92% -2897.77%
EBITD margin - -2845.84%
Return on average assets -85.43% -250.82%
Return on average equity -98.09% -706.62%
Employees 32 -
CDP Score - -


2800 Patton Rd
SAINT PAUL, MN 55113-1100
United States - Map
+1-651-6343003 (Phone)
+1-651-6343212 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ReShape Medical, Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company's initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company's VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

Officers and directors

Dan W. Gladney Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Scott P. Youngstrom Chief Financial Officer, Chief Compliance Officer
Age: 57
Bio & Compensation  - Reuters
Naqeeb A. Ansari Senior Vice President - Sales
Age: 56
Bio & Compensation  - Reuters
Paul F. Hickey Senior Vice President - Marketing and Reimbursement
Age: 52
Bio & Compensation  - Reuters
Peter M. Delange Senior Vice President - Operations and Business Development
Age: 48
Bio & Compensation  - Reuters
Gary D. Blackford Director
Age: 60
Bio & Compensation  - Reuters
Michael Y. Mashaal M.D. Director
Age: 43
Bio & Compensation  - Reuters
Lori Courtney McDougal Director
Age: 56
Bio & Compensation  - Reuters
Bobby I. Griffin Independent Director
Age: 79
Bio & Compensation  - Reuters
Jon T. Tremmel Independent Director
Age: 70
Bio & Compensation  - Reuters